Transcutaneous electrical nerve stimulation

Transcutaneous electrical nerve stimulation (TENS or TNS) is the use of electric current produced by a device to stimulate the nerves for therapeutic purposes. TENS, by definition, covers the complete range of transcutaneously applied currents used for nerve excitation although the term is often used with a more restrictive intent, namely to describe the kind of pulses produced by portable stimulators used to reduce pain. The unit is usually connected to the skin using two or more electrodes which are typically conductive gel pads. A typical battery-operated TENS unit is able to modulate pulse width, frequency, and intensity. Generally, TENS is applied at high frequency (>50 Hz) with an intensity below motor contraction (sensory intensity) or low frequency (<10 Hz) with an intensity that produces motor contraction. More recently, many TENS units use a mixed frequency mode which alleviates tolerance to repeated use. Intensity of stimulation should be strong but comfortable with greater intensities, regardless of frequency, producing the greatest analgesia. [1] While the use of TENS has proved effective in clinical studies, there is controversy over which conditions the device should be used to treat.[2]

This article is about the nerve therapy device. For the muscle stimulation device, see Electrical muscle stimulation.
"TENS" redirects here. For other uses, see TENS (disambiguation).
Transcutaneous electrical nerve stimulation
A four-lead TENS unit with two channels (two lead wires per channel)
MeSHD004561

Medical uses

Pain

Transcutaneous electrical nerve stimulation is a commonly used treatment approach to alleviate acute and chronic pain by reducing the sensitization of dorsal horn neurons, elevating levels of gamma-aminobutyric acid and glycine, and inhibiting glial activation.[3] However, many systematic reviews and meta analyses assessing clinical trials looking at the effectiveness of using TENS to reduce different sources of pain have been inconclusive due to a lack of high quality and unbiased evidence.[4][5] Potential benefits of TENS treatment include the safety, relative low cost, the ability to self-administer, and availability over the counter without a prescription.[4] In principle, an adequate intensity of stimulation is necessary to achieve pain relief with TENS.[6][7] An analysis of treatment fidelity (meaning that the delivery of TENS in a trial was in accordance with current clinical advice, such as using "a strong but comfortable sensation" and suitable, frequent treatment durations) showed that higher fidelity trials tended to have a positive outcome.[8]

Acute pain

For people with recent onset pain (less than three months) such as pain associated with surgery, trauma, and/or medical procedures, TENS may be better than placebo in some cases, however the evidence of benefit is very weak.[4]

Musculoskeletal and neck/back pain

There is some evidence to support a benefit of using TENS in chronic musculoskeletal pain.[9] Results from a task force on neck pain in 2008, found no clinically significant benefit to TENS for the treatment of neck pain when compared to a placebo treatment. A 2010 review did not find evidence to support the use of TENS for chronic low back pain.[10][11]

Another study examining knee osteoarthritis (KOA) patients supported that TENS demonstrated a better efficacy and safety profile than weak opiates. Given the age and comorbidities of the KOA population being generally older, often prone to polypharmacy and sensitive to adverse reactions, TENS could be a relevant non-pharmacological therapeutic alternative to pharmacological analgesics for the management of knee osteoarthritis pain.[12]

Neuropathy and phantom limb pain

There is tentative evidence that it may be useful for painful diabetic neuropathy.[10] As of 2015, the efficacy of TENS therapy for phantom limb pain is not known as no randomized controlled trials have been performed.[13]

A few studies have shown objective evidence that TENS may modulate or suppress pain signals in the brain. One used evoked cortical potentials to show that electric stimulation of peripheral A-beta sensory fibers reliably suppressed A-delta fiber nociceptive (pain perception) processing.[14] Two other studies used functional magnetic resonance imaging (fMRI): one showed that high-frequency TENS produced a decrease in pain-related cortical activations in patients with carpal tunnel syndrome,[15] while the other showed that low-frequency TENS decreased shoulder impingement pain and modulated pain-induced activation in the brain.[16]

Labor and menstrual pain

Earlier studies have stated that TENS "has been shown not to be effective in postoperative and labour pain." These studies also had questionable ability to truly blind the patients.[17][18] However, more recent studies have shown that TENS was "effective for relieving labour pain, and they are well considered by pregnant participants."[19] One study also showed that there was a significant change in how soon the laboring mothers took to request pharmacologic pain management, like the epidural. The group with the TENS waited five additional hours. Both groups were satisfied with the pain relief that they had from their choices. No maternal, infant, or labor problems were noted.[20] There is tentative evidence that TENS may be helpful for treating pain from dysmenorrhoea, however further research is required.[21][22]

Cancer pain

Non-pharmacological treatment options for people experiencing pain caused by cancer are much needed, however, it is not clear from the weak studies that have been published if TENS is an effective approach.[23][24]

Bladder function

Percutaneous and transcutaneous electrical nerve stimulation in the tibial nerve have been used in the treatment of overactive bladder and urinary retention.[25][26] Sometimes it is also done in the sacrum.[27] Systematic review studies have shown limited evidence on the effectiveness, and more quality research is needed.[27][28][29] A major trial found that in a care home context transcutaneous posterior tibial nerve stimulation did not improve urinary incontinence.[30]

Dentistry

TENS has been extensively used in non-odontogenic orofacial pain relief.[31] In addition, TENS and ultra low frequency-TENS (ULF-TENS) are commonly employed in diagnosis and treatment of temporomandibular joint dysfunction (TMD).[31] Further clinical studies are required to determine its efficacy.[31]

Tremor

A wearable neuromodulation device that delivers electrical stimulation to nerves in the wrist is now available by prescription. Worn around the wrist, it acts as a non-invasive treatment for those living with essential tremor.[32] The stimulator has electrodes that are placed circumferentially around a patient's wrist. Positioning the electrodes on generally opposing sides of the target nerve can result in improved stimulation of the nerve.[33] In clinical trials reductions in hand tremors were reported following noninvasive median and radial nerve stimulation.[34]

Transcutaneous afferent patterned stimulation (TAPS) is a tremor-customized therapy, based on the patient's measured tremor frequency, and is delivered transcutaneously to the median and radial nerves of a patient's wrist. The patient specific TAPS stimulation is determined through a calibration process performed by the accelerometer and microprocessor on the device.[35]

The Cala ONE delivers TAPS in a wrist-worn device that is calibrated to treat tremor symptoms. Cala ONE received de novo FDA clearance in April 2018 for the transient relief of hand tremors in adults with essential tremor and is currently marketed as Cala Trio.[35]

Contraindications

People who have implanted electronic medical devices including pacemakers and cardiodefibrillators are not suggested to use TENS.[4] In addition, caution should be taken before using TENS in those who are pregnant, have epilepsy, have an active malignancy, have deep vein thrombosis, have skin that is damaged, or are frail.[4]

Side effects

Overall, TENS has been found to be safe compared with pharmaceutical medications for treating pain.[4] Potential side effects include skin itching near the electrodes and mild redness of the skin (erythema).[4] Some people also report that they dislike the sensation associated with TENS.[4]

Device types

The TENS device acts to stimulate the sensory nerves and a small portion of the peripheral motor nerves; the stimulation causes multiple mechanisms to trigger and manage the sense of pain in a patient. TENS operates by two main mechanisms: it stimulates competing sensory neurons at the pain perception gate, and it stimulates the opiate response.[36] The mechanism that will be used varies with the type of device.

The table below lists the types of devices:

Parameters Patient's feelings Locations of the electrodes Purpose of therapy Therapy instructions How to relieve pain
Conventional TENS Low amplitude and high frequency (90–130 Hz)[37] A strong but painless sensation of impact and minimal muscular activity On the skin, in the pain spot Stimulate big-diameter nerve fibers, Aβ, for local pain relief. Use as needed Pain relief is normally quick both in and after the therapy sessions
AL-TENS High amplitude and low frequency (1–5 Hz transmissions) A strong but painless sensation of strained muscles Top of the muscle in a sore muscle area to activate the motor nerves. Stimulate the narrow-diameter skin nerve fibers as well as the Aδ motor fibers for pain relief in the segmental space around the area of pain. For a limited use of 20 to 30 minutes at a time[38] A response delay may occur
Intense TENS High amplitude Painful sensation of electrical impact in this area On the skin area proximal to the spot of pain[39] Stimulate narrow-diameter Aδ skin nerve fibers and create a counterstimulus (it will ease the existing stimulus) For a short-term use of 5 to 15 minutes at a time A fast response within the therapy range and a delayed response after it

History

Electrical stimulation for pain control was used in ancient Rome, in AD 63. It was reported by Scribonius Largus that pain was relieved by standing on an electrical fish at the seashore.[40] In the 16th through the 18th centuries various electrostatic devices were used for headache and other pains. Benjamin Franklin was a proponent of this method for pain relief.[41] In the 19th century a device called the electreat, along with numerous other devices were used for pain control and cancer cures. Only the electreat survived into the 20th century, but was not portable, and had limited control of the stimulus. Development of the modern TENS unit is generally credited to C. Norman Shealy.[42]

Modern

The first modern, patient-wearable TENS was patented in the United States in 1974.[43] It was initially used for testing the tolerance of chronic pain patients to electrical stimulation before implantation of electrodes in the spinal cord dorsal column.[44] The electrodes were attached to an implanted receiver, which received its power from an antenna worn on the surface of the skin. Although intended only for testing tolerance to electrical stimulation, many of the patients said they received so much relief from the TENS itself that they never returned for the implant.

A number of companies began manufacturing TENS units after the commercial success of the Medtronic device became known. The neurological division of Medtronic, founded by Don Maurer, Ed Schuck and Charles Ray, developed a number of applications for implanted electrical stimulation devices for treatment of epilepsy, Parkinson's disease, and other disorders of the nervous system.

Today many people confuse TENS with electrical muscle stimulation (EMS). EMS and TENS devices look similar, with both using long electric lead wires and electrodes. TENS is for blocking pain, where EMS is for stimulating muscles.

Research

As reported, TENS has different effects on the brain.[14] A randomized controlled trial in 2017 shown that sensory ULF-TENS applied on the skin proximally to trigeminal nerve, reduced the effect of acute mental stress assessed by heart rate variability (HRV).[45] Further high quality studies are required to determine the effectiveness of TENS for treating dementia.[46][47]

A head-mounted TENS device called Cefaly was approved by the United States Food and Drug Administration (FDA), in March 2014, for the prevention of migraines. The Cefaly device was found effective in preventing migraine attacks in a randomized sham-controlled trial.[48] This was the first TENS device the FDA approved for pain prevention, as opposed to pain suppression.[49]

A study performed on healthy human subjects demonstrates that repeated application of TENS can generate analgesic tolerance within five days, reducing its efficacy.[50] The study noted that TENS causes the release of endogenous opioids, and that the analgesia is likely due to opioid tolerance mechanisms.[50]

The pain reduction ability of TENS is unconfirmed by sufficient randomized controlled trials so far. One meta-analysis of several hundred TENS studies concluded that there was a significant overall reduction of pain intensity due to TENS, but there were too few participants and controls to be entirely certain of their validity. Therefore, the authors downgraded their confidence in the results by two levels, to low-certainty.[51]

Safety

There are several anatomical locations where TENS electrodes are contraindicated:

  • Over the eyes due to the risk of increasing intraocular pressure[52]
  • Transcerebrally[53]
  • On the front of the neck due to the risk of an acute hypotension (through a vasovagal response) or even a laryngospasm[52][54]
  • Through the chest using anterior and posterior electrode positions,[52] or other transthoracic applications understood as "across a thoracic diameter"; this does not preclude coplanar applications[54]
  • Internally, except for specific applications of dental, vaginal, and anal stimulation that employ specialized TENS units[52]
  • On broken skin areas or wounds, although it can be placed around wounds[52]
  • Over a tumor/malignancy (based on in vitro experiments where electricity promotes cell growth)[52][54]
  • Directly over the spinal column

TENS used across an artificial cardiac pacemaker (or other indwelling stimulator, including across its leads) may cause interference and failure of the implanted device. Serious accidents have been recorded in cases when this principle was not observed. A 2009 review in this area suggests that electrotherapy, including TENS, is "best avoided" in patients with pacemakers or implantable cardioverter-defibrillators (ICDs). They add that "there is no consensus and it may be possible to safely deliver these modalities in a proper setting with device and patient monitoring", and recommend further research. The review found several reports of ICDs administering inappropriate treatment due to interference with TENS devices, but notes that the reports on pacemakers are mixed: some non-programmable pacemakers were inhibited by TENS, but others were unaffected or auto-reprogrammed.[55]

The use of TENS is likely to be less effective on areas of numb skin or decreased sensation due to nerve damage. It may also cause skin irritation due to the inability to feel currents until they are too high.[52] There is an unknown level of risk when placing electrodes over an infection (possible spreading due to muscle contractions), but cross contamination with the electrodes themselves is of greater concern.[56] TENS should also be used with caution in people with epilepsy or pregnant women; do not use over area of the uterus as the effects of electrical stimulation over the developing fetus are not known.[54][57]

See also

References
  1. Robinson AJ, Snyder-Mackler L (2007). Clinical Electrophysiology: Electrotherapy and Electrophysiologic Testing (Third ed.). Lippincott Williams & Wilkins. ISBN 978-0781744843.
  2. DeSantana JM, Walsh DM, Vance C, Rakel BA, Sluka KA (December 2008). "Effectiveness of transcutaneous electrical nerve stimulation for treatment of hyperalgesia and pain". Current Rheumatology Reports. 10 (6): 492–499. doi:10.1007/s11926-008-0080-z. PMC 2746624. PMID 19007541.
  3. Huang J, Yang C, Zhao K, Zhao Z, Chen Y, Wang T, Qu Y. "Transcutaneous Electrical Nerve Stimulation in Rodent Models of Neuropathic Pain: A Meta-Analysis". Front. Neurosci. 2022 Jan 31;16:831413. doi:10.3389/fnins.2022.831413. PMID 35173577; PMC PMC8841820.
  4. Johnson MI, Paley CA, Howe TE, Sluka KA (June 2015). "Transcutaneous electrical nerve stimulation for acute pain". The Cochrane Database of Systematic Reviews. 2021 (6): CD006142. doi:10.1002/14651858.CD006142.pub3. PMC 8094447. PMID 26075732.
  5. Gibson W, Wand BM, Meads C, Catley MJ, O'Connell NE (April 2019). "Transcutaneous electrical nerve stimulation (TENS) for chronic pain - an overview of Cochrane Reviews". The Cochrane Database of Systematic Reviews. 4 (4): CD011890. doi:10.1002/14651858.CD011890.pub3. PMC 6446021. PMID 30941745.
  6. Bjordal JM, Johnson MI, Ljunggreen AE (2003). "Transcutaneous electrical nerve stimulation (TENS) can reduce postoperative analgesic consumption. A meta-analysis with assessment of optimal treatment parameters for postoperative pain". European Journal of Pain. 7 (2): 181–188. doi:10.1016/S1090-3801(02)00098-8. PMID 12600800. S2CID 24737458.
  7. Rakel B, Frantz R (October 2003). "Effectiveness of transcutaneous electrical nerve stimulation on postoperative pain with movement". The Journal of Pain. 4 (8): 455–464. doi:10.1067/S1526-5900(03)00780-6. PMID 14622666.
  8. Bennett MI, Hughes N, Johnson MI (June 2011). "Methodological quality in randomised controlled trials of transcutaneous electric nerve stimulation for pain: low fidelity may explain negative findings". Pain. 152 (6): 1226–1232. doi:10.1016/j.pain.2010.12.009. PMID 21435786. S2CID 25712472.
  9. Johnson M, Martinson M (July 2007). "Efficacy of electrical nerve stimulation for chronic musculoskeletal pain: a meta-analysis of randomized controlled trials". Pain. 130 (1–2): 157–165. doi:10.1016/j.pain.2007.02.007. PMID 17383095. S2CID 26643050.
  10. Dubinsky RM, Miyasaki J (January 2010). "Assessment: efficacy of transcutaneous electric nerve stimulation in the treatment of pain in neurologic disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology". Neurology. 74 (2): 173–176. doi:10.1212/WNL.0b013e3181c918fc. PMID 20042705.
  11. Khadilkar A, Odebiyi DO, Brosseau L, Wells GA (October 2008). Brosseau L (ed.). "Transcutaneous electrical nerve stimulation (TENS) versus placebo for chronic low-back pain". The Cochrane Database of Systematic Reviews. 2008 (4): CD003008. doi:10.1002/14651858.CD003008.pub3. PMC 7138213. PMID 18843638.
  12. Maheu E, Soriot-Thomas S, Noel E, Ganry H, Lespessailles E, Cortet B (2022). "Wearable transcutaneous electrical nerve stimulation (actiTENS®) is effective and safe for the treatment of knee osteoarthritis pain: a randomized controlled trial versus weak opioids". Therapeutic Advances in Musculoskeletal Disease. 14: 1759720X211066233. doi:10.1177/1759720X211066233. PMC 8777341. PMID 35069809.
  13. Johnson MI, Mulvey MR, Bagnall AM (August 2015). "Transcutaneous electrical nerve stimulation (TENS) for phantom pain and stump pain following amputation in adults". The Cochrane Database of Systematic Reviews. 8 (4): CD007264. doi:10.1002/14651858.CD007264.pub3. PMC 7209768. PMID 26284511.
  14. Ellrich J, Lamp S (October 2005). "Peripheral nerve stimulation inhibits nociceptive processing: an electrophysiological study in healthy volunteers". Neuromodulation. 8 (4): 225–232. doi:10.1111/j.1525-1403.2005.00029.x. PMID 22151549. S2CID 22850373.
  15. Kara M, Ozçakar L, Gökçay D, Ozçelik E, Yörübulut M, Güneri S, et al. (August 2010). "Quantification of the effects of transcutaneous electrical nerve stimulation with functional magnetic resonance imaging: a double-blind randomized placebo-controlled study". Archives of Physical Medicine and Rehabilitation. 91 (8): 1160–1165. doi:10.1016/j.apmr.2010.04.023. PMID 20684895.
  16. Kocyigit F, Akalin E, Gezer NS, Orbay O, Kocyigit A, Ada E (September 2012). "Functional magnetic resonance imaging of the effects of low-frequency transcutaneous electrical nerve stimulation on central pain modulation: a double-blind, placebo-controlled trial". The Clinical Journal of Pain. 28 (7): 581–588. doi:10.1097/AJP.0b013e31823c2bd7. PMID 22699130. S2CID 22274615.
  17. McQuay HJ, Moore RA, Eccleston C, Morley S, Williams AC (July 1997). "Systematic review of outpatient services for chronic pain control". Health Technology Assessment. 1 (6): i–iv, 1–135. doi:10.3310/hta1060. PMID 9483161.
  18. van der Spank JT, Cambier DC, De Paepe HM, Danneels LA, Witvrouw EE, Beerens L (November 2000). "Pain relief in labour by transcutaneous electrical nerve stimulation (TENS)". Archives of Gynecology and Obstetrics. 264 (3): 131–136. doi:10.1007/s004040000099. PMID 11129512. S2CID 1076157.
  19. Báez-Suárez A, Martín-Castillo E, García-Andújar J, García-Hernández JÁ, Quintana-Montesdeoca MP, Loro-Ferrer JF (November 2018). "Evaluation of different doses of transcutaneous nerve stimulation for pain relief during labour: a randomized controlled trial". Trials. 19 (1): 652. doi:10.1186/s13063-018-3036-2. PMC 6258317. PMID 30477529.
  20. Santana LS, Gallo RB, Ferreira CH, Duarte G, Quintana SM, Marcolin AC (January 2016). "Transcutaneous electrical nerve stimulation (TENS) reduces pain and postpones the need for pharmacological analgesia during labour: a randomised trial". Journal of Physiotherapy. 62 (1): 29–34. doi:10.1016/j.jphys.2015.11.002. PMID 26701166.
  21. Igwea SE, Tabansi-Ochuogu CS, Abaraogu UO (August 2016). "TENS and heat therapy for pain relief and quality of life improvement in individuals with primary dysmenorrhea: A systematic review". Complementary Therapies in Clinical Practice. 24: 86–91. doi:10.1016/j.ctcp.2016.05.001. PMID 27502806.
  22. Arik MI, Kiloatar H, Aslan B, Icelli M (2020-08-29). "The effect of TENS for pain relief in women with primary dysmenorrhea: A systematic review and meta-analysis". Explore. 18 (1): 108–113. doi:10.1016/j.explore.2020.08.005. PMID 32917532. S2CID 221637541.
  23. Hurlow A, Bennett MI, Robb KA, Johnson MI, Simpson KH, Oxberry SG (March 2012). "Transcutaneous electric nerve stimulation (TENS) for cancer pain in adults". The Cochrane Database of Systematic Reviews. 2012 (3): CD006276. doi:10.1002/14651858.CD006276.pub3. PMC 6669272. PMID 22419313.
  24. Eccleston C, Fisher E, Thomas KH, Hearn L, Derry S, Stannard C, et al. (November 2017). "Interventions for the reduction of prescribed opioid use in chronic non-cancer pain". The Cochrane Database of Systematic Reviews. 11 (5): CD010323. doi:10.1002/14651858.CD010323.pub3. PMC 6486018. PMID 29130474.
  25. Agost-González A, Escobio-Prieto I, Pareja-Leal AM, Casuso-Holgado MJ, Blanco-Diaz M, Albornoz-Cabello M (July 2021). "Percutaneous versus Transcutaneous Electrical Stimulation of the Posterior Tibial Nerve in Idiopathic Overactive Bladder Syndrome with Urinary Incontinence in Adults: A Systematic Review". Healthcare. 9 (7): 879. doi:10.3390/healthcare9070879. PMC 8306496. PMID 34356261.
  26. Coolen RL, Groen J, Scheepe JR, Blok BF (September 2021). "Transcutaneous Electrical Nerve Stimulation and Percutaneous Tibial Nerve Stimulation to Treat Idiopathic Nonobstructive Urinary Retention: A Systematic Review". European Urology Focus. 7 (5): 1184–1194. doi:10.1016/j.euf.2020.09.019. PMID 33268327. S2CID 226342032.
  27. Booth J, Connelly L, Dickson S, Duncan F, Lawrence M (February 2018). "The effectiveness of transcutaneous tibial nerve stimulation (TTNS) for adults with overactive bladder syndrome: A systematic review" (PDF). Neurourology and Urodynamics. 37 (2): 528–541. doi:10.1002/nau.23351. PMID 28731583. S2CID 206304402.
  28. Ghavidel-Sardsahra A, Ghojazadeh M, Rahnama'I MS, Naseri A, Yazdandoost S, Khezerloo T, et al. (February 2022). "Efficacy of percutaneous and transcutaneous posterior tibial nerve stimulation on idiopathic overactive bladder and interstitial cystitis/painful bladder syndrome: A systematic review and meta-analysis". Neurourology and Urodynamics. 41 (2): 539–551. doi:10.1002/nau.24864. PMID 35032328. S2CID 247170572.
  29. Yang DY, Zhao LN, Qiu MX (May 2021). "Treatment for overactive bladder: A meta-analysis of transcutaneous tibial nerve stimulation versus percutaneous tibial nerve stimulation". Medicine. 100 (20): e25941. doi:10.1097/MD.0000000000025941. PMC 8137095. PMID 34011072.
  30. Booth J, Aucott L, Cotton S, Davis B, Fenocchi L, Goodman C, et al. (June 2021). "Tibial nerve stimulation compared with sham to reduce incontinence in care home residents: Electric RCT". Health Technology Assessment. 25 (41): 1–110. doi:10.3310/hta25410. PMC 8273680. PMID 34167637.
  31. Chipaila N, Sgolastra F, Spadaro A, Pietropaoli D, Masci C, Cattaneo R, Monaco A (April 2014). "The effects of ULF-TENS stimulation on gnathology: the state of the art". Cranio. 32 (2): 118–130. doi:10.1179/0886963413Z.00000000018. PMID 24839723. S2CID 22320755.
  32. "De Novo Classification Request for Cala One" (PDF). U.S. Food and Drug Administration.
  33. Pahwa R, Dhall R, Ostrem J, Gwinn R, Lyons K, Ro S, et al. (July 2019). "An Acute Randomized Controlled Trial of Noninvasive Peripheral Nerve Stimulation in Essential Tremor". Neuromodulation. 22 (5): 537–545. doi:10.1111/ner.12930. PMC 6766922. PMID 30701655.
  34. Lin PT, Ross EK, Chidester P, Rosenbluth KH, Hamner SR, Wong SH, et al. (July 2018). "Noninvasive neuromodulation in essential tremor demonstrates relief in a sham-controlled pilot trial". Movement Disorders. 33 (7): 1182–1183. doi:10.1002/mds.27350. PMC 6174932. PMID 29663525.
  35. "De Novo Classification Request for Cala One" (PDF). FDA.
  36. Hall JE, Guyton AC. Guyton and Hall textbook of medical physiology. OCLC 434319356. Retrieved 29 March 2021 – via Worldcat.
  37. Ebers K. "The 3 different TENS stimulation types". Axion. Retrieved 29 March 2021.
  38. Nnoaham KE, Kumbang J (July 2008). Nnoaham KE (ed.). "Transcutaneous electrical nerve stimulation (TENS) for chronic pain". The Cochrane Database of Systematic Reviews (3): CD003222. doi:10.1002/14651858.CD003222.pub2. PMID 18646088.
  39. "Transcutaneous Electrical Nerve Stimulation (TENS)". Physiopedia. Retrieved 29 March 2021.
  40. Jensen JE, Conn RR, Hazelrigg G, Hewett JE (1985). "The use of transcutaneous neural stimulation and isokinetic testing in arthroscopic knee surgery". The American Journal of Sports Medicine. 13 (1): 27–33. doi:10.1177/036354658501300105. PMID 3872082. S2CID 19217534.
  41. "Transcutaneous Electrical Nerve Stimulation: Side Effects & Uses".
  42. Dac Teoli, Jason An (2019). Transcutaneous Electrical Nerve Stimulation (TENS). StatPearls. PMID 30725873.
  43. Maurer, D "Transcutaneous stimulator and stimulation method" U.S. Patent 3,817,254, Publication date June 18, 1974
  44. Burton C (January 1974). "Instrumentation for dorsal column stimulator implantation". Surgical Neurology. 2 (1): 39–40. PMID 4810453.
  45. Monaco A, Cattaneo R, Ortu E, Constantinescu MV, Pietropaoli D (May 2017). "Sensory trigeminal ULF-TENS stimulation reduces HRV response to experimentally induced arithmetic stress: A randomized clinical trial". Physiology & Behavior. 173: 209–215. doi:10.1016/j.physbeh.2017.02.014. PMID 28213205. S2CID 1816117.
  46. Cameron M, Lonergan E, Lee H (2003-07-21). "Transcutaneous electrical nerve stimulation (TENS) for dementia". The Cochrane Database of Systematic Reviews. 2003 (3): CD004032. doi:10.1002/14651858.CD004032. PMC 6768999. PMID 12917999.
  47. Abraha I, Rimland JM, Trotta FM, Dell'Aquila G, Cruz-Jentoft A, Petrovic M, et al. (March 2017). "Systematic review of systematic reviews of non-pharmacological interventions to treat behavioural disturbances in older patients with dementia. The SENATOR-OnTop series". BMJ Open. 7 (3): e012759. doi:10.1136/bmjopen-2016-012759. PMC 5372076. PMID 28302633.
  48. Schoenen J, Vandersmissen B, Jeangette S, Herroelen L, Vandenheede M, Gérard P, Magis D (February 2013). "Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial". Neurology. 80 (8): 697–704. doi:10.1212/WNL.0b013e3182825055. hdl:2268/216189. PMID 23390177. S2CID 38716692.
  49. "FDA allows marketing of first medical device to prevent migraine headaches". fda.gov.
  50. Liebano RE, Rakel B, Vance CG, Walsh DM, Sluka KA (February 2011). "An investigation of the development of analgesic tolerance to TENS in humans". Pain. 152 (2): 335–342. doi:10.1016/j.pain.2010.10.040. PMC 3027071. PMID 21144659.
  51. Johnson MI, Paley CA, Jones G, Mulvey MR, Wittkopf PG (February 2022). "Efficacy and safety of transcutaneous electrical nerve stimulation (TENS) for acute and chronic pain in adults: a systematic review and meta-analysis of 381 studies (the meta-TENS study)". BMJ Open. 12 (2): e051073. doi:10.1136/bmjopen-2021-051073. PMC 8845179. PMID 35144946.
  52. Watson, p. 266
  53. Bracciano AG (2008). Physical Agent Modalities: Theory and Application for the Occupational Therapist (2 ed.). Slack Incorporated. p. 232. ISBN 978-1556426490.
  54. Robertson, p. 159
  55. Digby GC, Daubney ME, Baggs J, Campbell D, Simpson CS, Redfearn DP, et al. (July 2009). "Physiotherapy and cardiac rhythm devices: a review of the current scope of practice". Europace. 11 (7): 850–859. doi:10.1093/europace/eup102. PMID 19411677.
  56. Robertson, p. 160
  57. Watson, p. 265
Books cited
  • Robertson VJ, Ward A, Low J, Reed A (2006). Electrotherapy Explained: Principles and Practice (4th ed.). Butterworth-Heinemann (Elsevier). ISBN 978-0750688437.
  • Watson T (2008). Electrotherapy: evidence-based practice (12th ed.). Elsevier Health Sciences. ISBN 978-0443101793.

Further reading
Wikimedia Commons has media related to Transcutaneous electrical nerve stimulation.
  • Cekmen N, Salman B, Keles Z, Aslan M, Akcabay M (February 2007). "Transcutaneous electrical nerve stimulation in the prevention of postoperative nausea and vomiting after elective laparoscopic cholecystectomy". Journal of Clinical Anesthesia. 19 (1): 49–52. doi:10.1016/j.jclinane.2006.05.025. PMID 17321927.
  • Gan LS, Prochazka A, Bornes TD, Denington AA, Chan KM (March 2007). "A new means of transcutaneous coupling for neural prostheses". IEEE Transactions on Bio-Medical Engineering. 54 (3): 509–517. doi:10.1109/TBME.2006.886664. PMID 17355064. S2CID 9568471.
  • Ozawa M, Tsuchiyama K, Gomi R, Kurosaki F, Kawamoto Y, Aiba S (December 2006). "Neuroselective transcutaneous electric stimulation reveals body area-specific differences in itch perception". Journal of the American Academy of Dermatology. 55 (6): 996–1002. doi:10.1016/j.jaad.2006.08.032. PMID 17097397.
  • Vrbová G, Hudlicka O, Schaefer Centofanti K (2008). Application of Muscle/Nerve Stimulation in Health and Disease. Springer. ISBN 978-1402082320.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.